Trial Profile
A Phase I/II Study of the Safety, Pharmacokinetics and Efficacy of Pomalidomide (CC-4047) in the Treatment of Kaposi Sarcoma in Individuals With or Without HIV
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Pomalidomide (Primary)
- Indications Kaposi's sarcoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 20 Jun 2023 Results published in the AIDS
- 18 May 2022 Status changed from active, no longer recruiting to completed.
- 16 Feb 2022 Results presented at the 29th Conference on Retroviruses and Opportunistic Infections